EA201992280A1 - Способы выявления соединений, модулирующих агрегацию тау-белка - Google Patents

Способы выявления соединений, модулирующих агрегацию тау-белка

Info

Publication number
EA201992280A1
EA201992280A1 EA201992280A EA201992280A EA201992280A1 EA 201992280 A1 EA201992280 A1 EA 201992280A1 EA 201992280 A EA201992280 A EA 201992280A EA 201992280 A EA201992280 A EA 201992280A EA 201992280 A1 EA201992280 A1 EA 201992280A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tau protein
identification
methods
protein aggregation
compounds modulating
Prior art date
Application number
EA201992280A
Other languages
English (en)
Inventor
Роза Креспо Родригес
Константин Адриан Апетри
Original Assignee
Янссен Вэксинс Энд Превеншн Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Вэксинс Энд Превеншн Б.В. filed Critical Янссен Вэксинс Энд Превеншн Б.В.
Publication of EA201992280A1 publication Critical patent/EA201992280A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

В настоящем изобретении представлен способ in vitro обеспечения образования и/или выявления парных спиральных филаментов (PHF) тау-белка, включающий инкубирование смеси, содержащей препарат на основе тау-белка и полианионный кофактор, в течение предварительно заданного периода времени в условиях, стимулирующих образование PHF.
EA201992280A 2017-03-28 2018-03-27 Способы выявления соединений, модулирующих агрегацию тау-белка EA201992280A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17163426 2017-03-28
PCT/EP2018/057781 WO2018178080A1 (en) 2017-03-28 2018-03-27 Methods for detection of tau protein aggregation modulating compounds

Publications (1)

Publication Number Publication Date
EA201992280A1 true EA201992280A1 (ru) 2020-02-13

Family

ID=58464226

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992280A EA201992280A1 (ru) 2017-03-28 2018-03-27 Способы выявления соединений, модулирующих агрегацию тау-белка

Country Status (10)

Country Link
US (1) US11249093B2 (ru)
EP (1) EP3602046A1 (ru)
JP (1) JP2020515846A (ru)
KR (1) KR20190127860A (ru)
CN (1) CN110446925A (ru)
AU (1) AU2018241860A1 (ru)
CA (1) CA3055866A1 (ru)
EA (1) EA201992280A1 (ru)
SG (2) SG10202110737WA (ru)
WO (1) WO2018178080A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3053379A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9610829D0 (en) * 1996-05-23 1996-07-31 Medical Res Council Screening of agents for treatment of azlheimers disease
EP1019069A2 (en) * 1996-12-13 2000-07-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel methods for testing inhibitors of paired helical filaments and uses for treatment of alzheimer's disease
WO2001018546A2 (en) * 1999-09-09 2001-03-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Screening for inhibitors of 'paired helical filaments'
US7172875B2 (en) * 2003-02-18 2007-02-06 The Ohio State University Research Foundation Identifying inhibitors of intracellular protein fibrillization
US20070218491A1 (en) 2006-02-08 2007-09-20 Oligomerix, Inc. Oligomerization of amyloid proteins
US9464122B2 (en) * 2008-08-20 2016-10-11 Oligomerix, Inc. Methods and compositions comprising tau oligomers
CA2813493C (en) * 2010-10-11 2019-07-09 University Of Zurich Human anti-tau antibodies
US20130337463A1 (en) * 2010-11-05 2013-12-19 The Trustees Of The University Of Pennsylvania Cell-Based Models of Neurodegenerative Disease
WO2012118935A1 (en) * 2011-03-03 2012-09-07 Proteotech Inc Compounds for the treatment of neurodegenerative diseases
LT2935326T (lt) * 2012-12-21 2020-12-10 Biogen Ma Inc. Žmogaus antikūnai prieš tau baltymą
WO2016123401A1 (en) * 2015-01-28 2016-08-04 University Of Delaware Detection of disease-associated tau protein conformations and applications thereof
KR20200007836A (ko) * 2017-04-24 2020-01-22 머캅터 디스커버리즈, 인크. 신경계 질환을 치료하기 위한 티올 화합물의 용도
EP3784687A1 (en) * 2018-04-27 2021-03-03 Ecole Polytechnique Federale De Lausanne (Epfl) A method for preparing phfs-like tau aggregates

Also Published As

Publication number Publication date
US11249093B2 (en) 2022-02-15
WO2018178080A1 (en) 2018-10-04
CA3055866A1 (en) 2018-10-04
US20200025777A1 (en) 2020-01-23
AU2018241860A1 (en) 2019-09-19
JP2020515846A (ja) 2020-05-28
EP3602046A1 (en) 2020-02-05
SG10202110737WA (en) 2021-11-29
SG11201908085XA (en) 2019-10-30
KR20190127860A (ko) 2019-11-13
CN110446925A (zh) 2019-11-12

Similar Documents

Publication Publication Date Title
EA201891087A1 (ru) Ингибиторы ret
EA201790755A1 (ru) Модуляция стимулирующих и нестимулирующих миелоидных клеток
CY1120937T1 (el) Φαρμακευτικη μορφοποιηση αντισωματος anti-tnf-αλφα
BR112017009728A2 (pt) anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
EA202092000A1 (ru) Ингибиторы димеризации egfr и их использование
EA201890329A1 (ru) СОЕДИНЕНИЯ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ
AU2018230657A8 (en) Anti-C5 antibodies and uses thereof
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
MX2018010971A (es) Compuestos y métodos para modular la tirosina cinasa de bruton.
WO2015198243A3 (en) Compositions and methods for long acting proteins
EA201590025A1 (ru) Нехирургический способ лечения катаракты
WO2016065349A3 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
EA201790877A1 (ru) Подобный йогурту высокобелковый продукт на основе белка молочной сыворотки, ингредиент, подходящий для его получения, а также способ получения
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
EA201892325A1 (ru) Композиции и способы детектирования белков клетки-хозяина
MX2017005888A (es) Dispositivos, sistemas y metodos para la deteccion de analitos.
MX2019009546A (es) Anticuerpos anti-factor d y uso de los mismos.
EA202091366A1 (ru) Обесцвеченный изолят рапсового белка
MX2022003212A (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso.
MX2020011740A (es) Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso.
MX2020005555A (es) Construcciones inmunogenicas de peptidos de tau.
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
EA201992280A1 (ru) Способы выявления соединений, модулирующих агрегацию тау-белка
BR112016023768A2 (pt) processo de ostreicultura melhorado